Mi SciELO
Servicios personalizadosServicios Personalizados
Revista
Articulo
Español (pdf)
Articulo en XML
Referencias del artículo
Traducción automática
Enviar articulo por emailIndicadores
Citado por SciELO 
Accesos
Links relacionados
Citado por Google 
Similares en
SciELO 
Similares en Google
Compartir
Permalink
Revista de la OFIL
versión On-line ISSN 1699-714Xversión impresa ISSN 1131-9429
Resumen
ESTEBAN-CASADO, S; BARTOLOME-GARCIA, E; SANZ-MARQUEZ, S y PEREZ-ENCINAS, M. Management of angiotensin-converting enzyme inhibitors-related angioedema with icatibant. Rev. OFIL·ILAPHAR [online]. 2021, vol.31, n.3, pp.281-284. Epub 30-Mayo-2022. ISSN 1699-714X. https://dx.doi.org/10.4321/s1699-714x2021000300006.
Objetive:
To assess the effectiveness of icatibant in the management of angiotensin-converting enzyme inhibitor-induced angioedema (AII) in a hospital without a treatment guidance.
Methods:
Observational, retrospective and descriptive study. All patients diagnossed with AII and treated with icatibant 30 mg between May 2015-December 2017 were included. The primary and secondary end-points were: time to total resolution and time to first improvement; respectively.
Results:
Five patients, median age 76 years (46-81). Four women and a man. All of them Caucasian. Median time to total resolution and to first improvement: 23 hours (IQR 20.0-25.0) and 3 hours (IQR 3.0-6.0); respectively.
Conclusion:
The early start with the anti-bradicinergic therapy may be key to the AII evolution. To achieve the maximum effectiveness and to get reduced the associated morbidity, the ICU admission and the time to discharge, the development of local protocols considering the particularities of each center is highly necessary.
Palabras clave : Angioedema; angiotensin; converting enzyme inhibitors; icatibant; drug-related side effects and adverse reactions.
